How is Keytruda priced in the US?
Keytruda (pembrolizumab), Merck's blockbuster PD-1 inhibitor for cancers like melanoma and lung cancer, has a wholesale acquisition cost (WAC) of about $11,400 per 100 mg vial, or roughly $200 per mg. Dosing varies by weight and regimen (e.g., 200 mg every three weeks), leading to annual costs exceeding $150,000 for many patients before discounts.[1]
What drives its high list price?
Pricing reflects R&D costs for Keytruda's development, including over $1 billion in clinical trials across 30+ indications. Manufacturing involves complex biologics production, with high potency requirements for monoclonal antibodies. Merck sets prices to recover these amid low single-digit gross margins on sales, factoring in patent-protected exclusivity until at least 2028.[2]
Role of patents and market exclusivity
Keytruda's pricing holds due to strong patent protection on the drug substance, formulation, and methods of use, listed on DrugPatentWatch.com. Core composition patents expire in 2028, but method patents extend to 2035, deterring generics. No biosimilars are approved yet; challenges from Amgen and others are ongoing in court.[3] Exclusivity delays competition, sustaining premium pricing.
Discounts, rebates, and net pricing reality
List prices exceed actual costs: Merck offers 20-50% rebates to PBMs like CVS Caremark and insurers via the Patient Assistance Program. Net price per dose falls to $7,000-$9,000 after negotiations. Medicare's Inflation Reduction Act caps increases but allows negotiation starting 2028, potentially lowering prices 25-60%.[1][4]
How do competitors affect Keytruda's price?
Keytruda faces rivals like Bristol Myers' Opdivo (nivolumab, ~$140/mg WAC) and Roche's Tecentriq (atezolizumab, ~$160/mg). Cross-trial comparisons show similar efficacy, pressuring Merck to match discounts rather than raise prices. Market share battles (Keytruda at 50%+ of PD-1/PD-L1 sales) keep pricing competitive without undercutting.[5]
Global pricing differences and access issues
In Europe, Keytruda lists at €3,500-4,000 per dose (half US levels) due to HTA negotiations by bodies like NICE. Canada and Australia cap at 20-30% of US prices. Patients in low-income countries access via Merck's tiered pricing or generics in India, but US prices fund global R&D subsidies.[6]
What happens when patents expire?
Post-2028, biosimilars could enter, slashing prices 30-50% initially (e.g., Humira precedent). Merck may extend via new formulations or indications. Litigation over 'skinny labels' could delay this; watch Amgen's case.[3]
Sources
[1] GoodRx - Keytruda Pricing
[2] Merck SEC Filings - R&D Expenses
[3] DrugPatentWatch.com - Keytruda Patents
[4] CMS - Medicare Drug Price Negotiation
[5] Evaluate Pharma - PD-1 Market Share
[6] IQVIA - Global Oncology Pricing